Using CRT exposure and HMGB1 release as surrogate markers for drug-induced tumor cell immunogenicity, we found that OxP treatment indeed induced immunogenic effects on CT26-FL3 cells (Supplementary Fig. 2a, b). The gene discussed is HMGB1; the disease is neoplasm.